Table 5.
Median time to progression in patients with measurable disease at baseline (full analysis set).
| Category | All patients (N = 3246) | CNS metastasis (n = 51) | Prior chemotherapy (n = 194) | ECOG PS 2 (n = 112) | VM + prior chemotherapy (n = 146) | VM + ECOG PS 2 (n = 77) |
|---|---|---|---|---|---|---|
| n/N (%) | 1106/3246 | 18/51 | 98/194 | 45/112 | 82/146 | 33/77 |
| (34.1) | (35.3) | (50.5) | (40.2) | (56.2) | (42.9) | |
| Time to progression, months | 27.1 | NR | 18.4 | 19.5 | 13.7 | 18.8 |
| Median (95% CI) | (25.7-NR) | (15.5-NR) | (13.2–21.3) | (13.5-NR) | (9.0–19.5) | (11.0–24.5) |
CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; NR, not reached; VM, visceral metastases.
n: Total number of events included in the analysis. N: Total number of patients included in the analysis.